Here are the 10-Q quarterly reports from Balchem Corporation (BCPC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCPC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCPC filings page.
Balchem Corporation (BCPC) reported third-quarter net sales of $290.7 million, up 8.6% from a year earlier, and net earnings of $46.7 million, up 16.0%. Earnings from operations rose 14.4% to $62.4 million. Gross margin was 36.4% of sales versus 35.7% a year earlier. Human Nutrition & Health sales increased 8.1%, Animal Nutrition & Health 11.7%, and Specialty Products 4.5%.
For the first nine months of 2026, net sales were $845.4 million, up 9.3%, and net earnings were $131.6 million, up 13.8%. Management attributed sales growth to higher sales in Human Nutrition & Health and Animal Nutrition & Health and performance gases in Specialty Products. It cited favorable mix and manufacturing efficiencies in gross margin, partly offset by higher manufacturing input costs. Operating cash flow was $156.5 million, compared with $149.3 million in 2025. A July 24, 2026 credit agreement amendment increased the aggregate revolving commitment from $550 million to $650 million and extended maturity from July 27, 2027 to July 24, 2031. At September 30, 2026, $124.0 million was outstanding on the revolving loan, with $526.0 million available under the facility.
Balchem Corporation reported solid Q2 2026 results, with net sales of $283,997 thousand, up 11.2% year over year, and net earnings of $44,615 thousand, up 16.6%. Diluted EPS was $1.39 for the quarter and $2.63 for the first six months.
Growth was broad-based: Human Nutrition & Health sales increased 10.0%, Animal Nutrition & Health 15.0%, and Specialty Products 8.9%. Gross margin was 36.5% in the quarter versus 36.4% a year earlier, and 36.9% year to date versus 35.8%, helped by higher volumes, pricing, and mix, partly offset by higher input costs.
Operating cash flow reached $86,772 thousand for the first half, funding $17,138 thousand of capital investments, $30,772 thousand of dividends, and $44,484 thousand of share repurchases. Net borrowings under the revolving loan were $152,000 thousand with $398,000 thousand of availability, and a July 2026 amendment increased total revolving capacity to $650,000 thousand and extended maturity to 2031.
Balchem Corporation delivered higher first-quarter 2026 results, with net sales rising to $270.7 million from $250.5 million and net earnings increasing to $40.3 million from $37.1 million. Diluted EPS grew to $1.25 from $1.13.
Gross margin expanded to 37.3% of sales from 35.2%, supported by growth across Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, partly offset by higher raw material and compensation costs. Operating margin remained strong at about 20.5%.
Operating cash flow was $40.1 million, funding $6.3 million of capital and intangible investments, $30.8 million of dividends, and $15.7 million of share repurchases. Total assets were $1.69 billion, with a $169 million revolving loan balance and stockholders’ equity of $1.29 billion.
Comprehensive income was reduced by a $9.8 million other comprehensive loss, mainly from foreign currency translation. Management notes ongoing monitoring of geopolitical tensions and evolving U.S. tariff policies but does not currently expect a material impact on future results or cash flows based on available information.
Balchem (BCPC) reported stronger Q3 2025 results. Net sales rose to $267.6 million from $239.9 million, and net earnings increased to $40.3 million from $33.8 million. Diluted EPS was $1.24 versus $1.03. Gross margin expanded as cost of sales rose more slowly than revenue, lifting earnings from operations to $54.6 million from $48.0 million.
Growth was broad-based: Human Nutrition & Health sales were $174.1 million, Animal Nutrition & Health $56.4 million, and Specialty Products $35.7 million. For the nine months, operating cash flow reached $149.3 million, supporting share repurchases and debt reduction. The revolving loan balance declined to $154.0 million from $190.0 million, while cash increased to $65.1 million. Year‑to‑date, the company repurchased 333,594 shares at an average cost of $161.90.
The company noted an EU anti‑dumping investigation into choline chloride imports from China, with proposed definitive duties of 90.0% to 115.9% and final measures expected by the end of 2025. As of October 13, 2025, shares outstanding were 32,386,260.